Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)—Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
Abstract
Van Iersel et al 1 are to be commended for their important contribution towards a deeper understanding of the motivations and needs of healthy volunteers participating in early-phase (phase I) clinical trials. Their findings demonstrate that participation is driven by a combination of altruistic, practical and social factors, rather than financial compensation alone, while also highlighting healthy volunteers as an underutilized stakeholder group in early clinical development. Building on these insights and informed by our experience in implementing a large and diverse early-phase and clinical pharmacology portfolio at Novartis, we would like to encourage further expansion of this research in several areas:
Read the paper
Related studies
- In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets
- Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery
- Anti-phytopathogenic and plant growth promoting potential of endophytic fungi isolated from Dysoxylum gotadhora
- Mercury toxicity causes iron and sulfur deficiencies along with oxidative injuries in alfalfa (Medicago sativa)
- Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo
- Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.